Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING Phase 4

A Study of CDPATH™ to Help Manage and Treat Crohn's Disease

NCT04809363 · View on ClinicalTrials.gov ↗

Study Summary

CDPATH™ is a tool to help predict the potential for developing Crohn's disease related complications in certain adult participants within 3 years. The main aim of the study is to explore the use of CDPATH™ to describe a participant's risk profile and to have discussions with their doctor about the potential path of their Crohn's disease. The number of visits will be decided by the study clinic according to their standard practice.

Conditions Studied

Interventions

  • OTHER Blood Draw
  • OTHER CDPATH™

Study Locations (20)

California

  • VA Loma Linda Healthcare System — Loma Linda
  • United Medical Doctors — Murrieta
  • University of Southern California Medical Center — Newport Beach
  • Clinnova Research Solutions — Orange
  • University of California at Irvine Medical Center — Orange

Illinois

  • GI Alliance — Arlington Heights
  • GI Alliance — Gurnee
  • Comprehensive Gastrointestinal Health — Northbrook
  • Rockford Gastroenterology Associates, Ltd. — Rockford

Florida

  • West Central Gastroenterology d/b/a Gastro Florida — Clearwater
  • Gastroenterology Associates of Pensacola, PA — Pensacola

Iowa

  • Iowa Digestive Disease Center — Clive
  • University of Iowa Hospitals & Clinics — Iowa City

Arizona

  • Arizona Arthritis & Rheumatology Research, PLLC — Phoenix

Colorado

  • Kaiser Permanate of Colorado — Aurora

Connecticut

  • Medical Research Center of Connecticut, LLC — Hamden

Idaho

  • Grand Teton Research Group, PLL — Idaho Falls

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2021-06-25
Est. Completion 2026-09-12
Phase Phase 4

Sponsor

Takeda

387 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04809363

The ClinicalTrials.gov registry entry for NCT04809363 describes a study currently listed as active not recruiting. It is categorized as Phase 4, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 387 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 2 interventions — of which Blood Draw is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04809363 reports 20 study locations spanning 11 distinct geographic areas — top geographies include California, Illinois, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04809363 about?

NCT04809363 is a clinical study titled "A Study of CDPATH™ to Help Manage and Treat Crohn's Disease". CDPATH™ is a tool to help predict the potential for developing Crohn's disease related complications in certain adult participants within 3 years. The main aim of the study is to explore the use of CDPATH™ to describe a participant's risk profile and to have discussions with their doctor about the p...

What is the current status of trial NCT04809363?

This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2021-06-25. Estimated completion is 2026-09-12.

What conditions does trial NCT04809363 study?

This clinical trial studies the following conditions: Crohn's Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04809363?

The interventions under investigation include: Blood Draw (OTHER), CDPATH™ (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04809363?

This trial is sponsored by Takeda, which has 387 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04809363 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial